25 Impact of bleomycin (BLM) administration on the development of pulmonary toxicity in advanced germ cell tumours (GCT) receiving first-line chemotherapy (CT): A meta-analysis of randomized studies

2016 ◽  
Vol 15 (3) ◽  
pp. e25
Author(s):  
A. Necchi ◽  
K. Oualla ◽  
R. Miceli ◽  
G. Sonpavde ◽  
N. Nicolai ◽  
...  
Keyword(s):  
Germ Cell ◽  
Pulmonary Toxicity ◽  
Meta Analysis ◽  
Germ Cell Tumours ◽  
First Line ◽  
Randomized Studies ◽  
Line Chemotherapy

Epidemiology of male seminomatous (SGCT) and non-seminomatous germ cell tumours (NSGCT) and response to first line chemotherapy (CT) from a tertiary cancer centre in India.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e15553-e15553
Author(s):  
Saurabh shyamsunder Zanwar ◽  
Amit Joshi ◽  
Vanita Noronha ◽  
Vijay Maruti Patil ◽  
Nishitha Shetty ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumours ◽  
First Line ◽  
Cancer Centre ◽  
Line Chemotherapy

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

2020 ◽  
Author(s):  
Christian Daniel Fankhauser ◽  
Ben Tran ◽  
Manuel Pedregal ◽  
José Manuel Ruiz-Morales ◽  
Egon Gonzalez-Billalabeitia ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumours ◽  
Benefit Analysis ◽  
First Line ◽  
Prophylactic Anticoagulation ◽  
Risk Benefit Analysis ◽  
Line Chemotherapy

scholarly journals The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Hongqiong Yang ◽  
Yaojun Zhou ◽  
Liangzhi Wang ◽  
Tianyi Gu ◽  
Mengjia Lv ◽  
...  
Keyword(s):  
Response Rate ◽  
Meta Analysis ◽  
Gastroesophageal Junction ◽  
Objective Response ◽  
Progression Free Survival ◽  
Pooled Analysis ◽  
First Line ◽  
Free Survival ◽  
Gastroesophageal Junction Cancer ◽  
Line Chemotherapy

Five electronic databases were searched for eligible records. Outcomes were presented and analyzed according to the objective response rate (ORR), progression-free survival (PFS) rate, and overall survival (OS) rate. Five records involving 2,024 participants were included in the study. The pooled analysis of OS and PFS were longer with ramucirumab (RAM) therapy than without RAM for OS (odds ratio OR = 0.90 , 95% confidence interval CI = 0.82 – 1.00 , p = 0.05 ) and PFS ( OR = 0.74 , 95 % CI = 0.57 – 0.96 , p = 0.02 ). Moreover, compared with the current first-line chemotherapy, the OS ( OR = 0.93 , 95 % CI = 0.83 – 1.04 , p = 0.19 ) and PFS ( OR = 0.82 , 95 % CI = 0.64 – 1.06 , p = 0.13 ) results were not significantly higher with RAM. The ORRs of the patients in the RAM therapy groups were significantly higher than those in the groups without RAM ( OR = 1.40 , 95 % CI = 1.14 – 1.73 , p = 0.001 ).

Sign in / Sign up

Export Citation Format

Share Document